• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Dr. Reddy's working out deal with Danish company

      Dr Reddy's Laboratories Limited (DRL) is working out a deal with a Danish company with regard to the development of balaglitazone, a drug aimed at addressing the problem of Diabetes, according DRL chairman, K Anji Reddy.
      Replying to a shareholder's question at the DRL's 21st annual general meeting here on Wednesday, Reddy said that balaglitazone development was likely to materialise by next year. Phase II development of the drug has been completed.

      Earlier, addressing the AGM, Reddy said that DRL had developed an "innovative and unique" model for financing and sharing the risk of development of new drugs. Several potential partners have evinced keen interest in participating in such a model.

      "I am hopeful that we can progress the negotiations fairly rapidly and find a sustainable way to develop new drug candidates," he said, adding that DRL's model would ensure that returns to the company would be very attractive should the molecule be commercialised.

      In the past, DRL had retained commercial rights to India. The company would now have the option to retain commercial rights in larger territories.

      Referring to the company's initiative of entering the regulated markets of the US and Europe, Reddy said that DRL has robust products in the pipeline and commercial launches would pick up momentum in the next financial year.

      July 28, 2005


      Share this Article!

    Back to top^